文献速递糖尿病

改善糖尿病血糖控制的质量改进干预措施的经济学评价:系统综述与加权回归分析

Economic Evaluation of Quality Improvement Interventions Designed to Improve Glycemic Control in Diabetes: A Systematic Review and Weighted Regression Analysis.
PubMed 文献 · Diabetes Care · 2018-01-01

该系统综述纳入46项来自高收入国家的经济学评价,评估组织性质量改进(QI)干预对成人1型或2型糖尿病血糖控制的价值。19项随机对照试验(RCT)中,与常规照护相比,HbA1c相对下降0.26%(95%CI 0.17-0.35)或3 mmol/mol(2-4)。8项≤3年的RCT中,每例患者年增量净成本为116美元(95%CI -612至843美元);长期增量成本效果比(ICER)在3项RCT中为100,000-115,000美元/质量调整生命年(QALY),1项为50,000-99,999美元/QALY,4项为0-49,999美元/QALY,1项为优势。作者认为,降低HbA1c的多元化QI干预相对于常规照护似乎具有一般至良好的价值,取决于社会对健康改善的支付意愿。

要点

  • 19项RCT显示QI干预使HbA1c相对常规照护下降0.26%(95%CI 0.17-0.35)或3 mmol/mol(2-4)。
  • 8项≤3年RCT中,每例患者年增量净成本为116美元(95%CI -612至843美元)。
  • 长期ICER在3项RCT为100,000-115,000美元/QALY,1项为50,000-99,999美元/QALY,4项为0-49,999美元/QALY,1项为优势。

核心结论

  • 降低HbA1c的多元化QI干预相对于常规照护似乎具有一般至良好的价值,取决于社会对健康改善的支付意愿。

研究设计与样本

  • 系统综述与加权最小二乘回归分析,纳入来自高收入国家、评估组织性改变并报告项目相关和利用相关成本的英文研究,检索PubMed、EconLit、Centre for Reviews and Dissemination、纽约医学科学院灰色文献报告和WorldCat(2004年1月至2016年8月),最终纳入46项独特研究。

主要发现

  • 在19项RCT中,与常规照护相比,HbA1c下降0.26%(95%CI 0.17-0.35)或3 mmol/mol(2-4)。
  • 在8项持续≤3年的RCT中,每例患者年增量净成本为116美元(95%CI -612至843美元)。
  • 长期ICER在3项RCT中为100,000-115,000美元/QALY,在1项RCT中为50,000-99,999美元/QALY,在4项RCT中为0-49,999美元/QALY,在1项RCT中为优势。
  • 非RCT研究的结果更为有利。

关键数值与推荐

  • 在19项RCT中,HbA1c相对常规照护下降0.26%(95%CI 0.17-0.35)或3 mmol/mol(2-4)。
  • 在8项持续≤3年的RCT中,增量净成本为每例患者每年116美元(95%CI -612至843美元)。
  • 长期ICER:3项RCT为100,000-115,000美元/QALY,1项RCT为50,000-99,999美元/QALY,4项RCT为0-49,999美元/QALY,1项RCT为优势。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究设计多样。
  • 研究存在中等偏倚风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Quality improvement (QI) interventions can improve glycemic control, but little is known about their value. We systematically reviewed economic evaluations of QI interventions for glycemic control among adults with type 1 or type 2 diabetes. RESEARCH DESIGN AND METHODS: We used English-language studies from high-income countries that evaluated organizational changes and reported program and utilization-related costs, chosen from PubMed, EconLit, Centre for Reviews and Dissemination, New York Academy of Medicine's Grey Literature Report, and WorldCat (January 2004 to August 2016). We extracted data regarding intervention, study design, change in HbA1c, time horizon, perspective, incremental net cost (studies lasting ≤3 years), incremental cost-effectiveness ratio (ICER) (studies lasting ≥20 years), and study quality. Weighted least-squares regression analysis was used to estimate mean changes in HbA1c and incremental net cost. RESULTS: Of 3,646 records, 46 unique studies were eligible. Across 19 randomized controlled trials (RCTs), HbA1c declined by 0.26% (95% CI 0.17-0.35) or 3 mmol/mol (2 to 4) relative to usual care. In 8 RCTs lasting ≤3 years, incremental net costs were $116 (95% CI -$612 to $843) per patient annually. Long-term ICERs were $100,000-$115,000/quality-adjusted life year (QALY) in 3 RCTs, $50,000-$99,999/QALY in 1 RCT, $0-$49,999/QALY in 4 RCTs, and dominant in 1 RCT. Results were more favorable in non-RCTs. Our limitations include the fact that the studies had diverse designs and involved moderate risk of bias. CONCLUSIONS: Diverse multifaceted QI interventions that lower HbA1c appear to be a fair-to-good value relative to usual care, depending on society's willingness to pay for improvements in health.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Nuckols TK, Keeler E, Anderson LJ, et al. Economic Evaluation of Quality Improvement Interventions Designed to Improve Glycemic Control in Diabetes: A Systematic Review and Weighted Regression Analysis. Diabetes Care. 2018. PMID: 29678865. doi:10.2337/dc17-1495

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。